# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects

> **NCT05758428** · PHASE1 · COMPLETED · sponsor: **Nuance Pharma (shanghai) Co., Ltd** · enrollment: 28 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Ensifentrine
- **DRUG:** Ensifentrine

## Key facts

- **NCT ID:** NCT05758428
- **Lead sponsor:** Nuance Pharma (shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758428, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05758428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*